Vancouver, BC, Canada, August 25, 2021, Xebra Brands Ltd. (“Xebra”) is pleased to announce that it has entered into an agreement with New Age Nanotech, to license its clinically-backed, patent pending delivery technology for cannabinoids, Solutech™.
Solutech™ is one of the fastest-acting, most bioavailable and comprehensively studied delivery systems for cannabinoids, including THC and CBD, uniquely differentiated for relative oral bioavailability and absorption by a Phase I human clinical trial. Xebra’s license is exclusive in Mexico and Colombia, and non-exclusive in Europe and the rest of the Americas, including Canada, but limited to only California in the United States.
“This agreement with New Age allows Xebra to utilize Solutech™ IP in unlimited form factors, including edibles, beverages, topicals, and cosmetic, however, the agreement is most notable for one principal reason: no royalties are payable. The absence of royalty payments, gives Xebra a significant cost advantage over its peers, which will lead to healthier product margins, and better product pricing for consumers,” said Rodrigo Gallardo, President of Xebra.
“We’re pleased to partner with Xebra and introduce Solutech™ to Canadian consumers through the launch of Xebra’s Vicious Citrus THC Lemonade, which is planned for Spring 2022,” said Volker Berl, CEO of New Age.
Pursuant to the terms of the agreement, Xebra will issue six million common shares to New Age, for the fully paid-up right to produce and use Solutech™ in exclusive and non-exclusive territories. The agreement is effective immediately with an indefinite perpetual term, unless terminated under specific circumstances.
ABOUT SOLUTECH™
Infusing cannabis into products presents three major challenges: limited shelf-stability, poor absorption, and inconsistent dosing. An expert in oral delivery technologies, New Age Nanotech addresses these issues with its patent-pending solution, Solutech™ – a clear, pharmaceutical-grade, bioactive formulation, that is also low-cost to produce.
Solutech™ is the only cannabinoid infusion technology that has undergone Phase I human clinical trials for relative oral bioavailability and absorption, and it includes both major cannabinoids THC and CBD, and their metabolites. The Phase I, Health Canada-approved study, was led by KGK Science, a premier clinical research organization. Solutech™ demonstrated dramatically increased speed of absorption and elimination (fast onset and offset of effects), peak blood levels and rate of absorption, along with a consistent and desirable consumer experience. The Phase I trial is complete and results are pending publication.
ABOUT XEBRA
Xebra Brands Ltd., is a cannabis cultivation and product company, with global brands and intellectual property. Products cover wellness and leisure, and include beverages. Xebra is a cannabis early mover in Mexico and Holland, and holds licenses in Colombia. Vicious Citrus, a THC Lemonade is planned for launch in Canada in the spring of 2022. Xebra is completing a public listing and expects to trade on the CSE under the symbol XBRA in September 2021.
ABOUT NEW AGE NANOTECH
New Age Nanotech is enabling the world’s most innovative, clinically-backed, and consumer-focused products to improve health and wellness through Solutech™, the company’s flagship water-soluble delivery technology for cannabinoids. Solutech™ offers a fully characterized pharmacokinetic and pharmacodynamic profile for consumer products to champion safe & effective use. New Age Nanotech offers Solutech™ to CPG brands for the development and commercialization of innovative, convenient, and controlled-dose products that speak to the evolving needs of their consumers. For inquiries about Solutech™: (800) 210-9809 or [email protected].
For more information contact:
+1 (604) 418-6560
[email protected]
Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.’s (“XEBRA” or “XEBRA’S”) expectations in respect of its ability to successfully execute its business plan or business model; its ability to provide economic, environmental, social, or any benefits of any type, in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Colombia, Canada, the Netherlands, or elsewhere; its ability to raise capital and fund its ongoing operations; its ability to list its shares on a stock exchange or attain a public listing, its ability to successfully apply for and obtain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to cultivate, grow, or process hemp or cannabis in Mexico, Colombia, Canada, the Netherlands, or elsewhere; its ability to manufacture cannabis beverages, wellness products, or other products; its ability to commercialize or sell cannabis beverages, wellness products, or other products, in Mexico, Colombia, Canada, the Netherlands, or elsewhere; its ability to commercialize or to sell Vicious Citrus Lemonade in 2021 or at any time, in any jurisdiction; its ability to commercialize or to sell Elements wellness products in Mexico, in Colombia, or in any jurisdiction in 2021 or at any time; its ability to make cannabis beverages that taste good; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management’s expectations, beliefs and assumptions; events or developments that XEBRA expects to take place in the future; and general economic conditions. All statements, other than statements of historical facts, are forward-looking information and statements. The words “aim”, “believe”, “expect”, “anticipate”, “contemplate”, “target”, “intends”, “continue”, “plans”, “budget”, “estimate”, “may”, “will”, and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of XEBRA to generate sufficient revenues or to raise sufficient funds to carry out its business plan; the inability of Xebra to list its shares for trading on a stock exchange; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; and the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for license applications. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect XEBRA’s actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, XEBRA. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.